Healthcare
Stemtech Corporation(STEK)
Live Price
Offline$0.0001
+0.00% today
1Y Change
-99.42%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- +2.7%
- EPS Growth
- +51.2%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stemtech Corporation (STEK) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.4% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +2.7%, EPS growth of +51.2%, a dividend yield of 0.0%. What stands out right now is revenue +2.7%, EPS +51.2%, free cash flow +70.5% with operating margin -48.6% and ROIC 43.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines STEK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.7% vs +7.6% peer median
Operating Margin
Below sector median
-48.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2023 was reported on Sep 30, 2023, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +2.7% and EPS at +51.2%, with operating margin around -48.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2023 Sep 30, 2023 | โ | -21.3% | -7.0% | -28.0% |
2023 Jun 30, 2023 | โ | -21.3% | -7.0% | -28.0% |
2023 Mar 31, 2023 | โ | -21.3% | -7.0% | -28.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STEK
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
STEK Max Drawdown
-99.71%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STEK and SPY.
Company Overview
Stemtech Corporation
Other OTC
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. The company's products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood, and migrate them into tissues, where they can perform their daily function of renewal for optimal health. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. The company is based in Miramar, Florida.
- Leadership
- Charles S. Arnold
- IPO Date
- Nov 26, 2021
- Employees
- 1
- Street Address
- 10370 USA Today Way
- Mailing
- Naples, FL, 33025
- Region
- Naples, FL, US
- Reporting Currency
- USD
- Investor Line
- 954 715 6000
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- โ
Growth
- Revenue
- +2.7%
- EPS
- +51.2%
- Free Cash Flow
- +70.5%
Profitability
- Gross Margin
- 80.4%
- Operating Margin
- -48.6%
- Net Margin
- -79.2%
- ROE
- 56.5%
- ROIC
- 43.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.10
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.